# GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma

Source: https://onco.cc/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/  
OnCo record `paper-gog-0261-carcinosarcoma-powell-jco-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

For uterine carcinosarcoma, the standard breast and ovarian regimen carboplatin-paclitaxel was as effective as the older, more toxic paclitaxel-ifosfamide combination, simplifying treatment of this rare aggressive cancer.

## Summary

Phase 3 non-inferiority trial of 536 patients with stage I to IV, persistent or recurrent uterine carcinosarcoma (with a small ovarian carcinosarcoma cohort) randomised to paclitaxel-carboplatin or paclitaxel-ifosfamide.

Median overall survival was 37 versus 29 months (hazard ratio 0.87, non-inferior) and progression-free survival 16 versus 12 months, with more haematological toxicity but less confusion and genitourinary toxicity with carboplatin.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2022
- DOI: 10.1200/JCO.21.02050
- Authors: Powell MA, Filiaci VL, Hensley ML, et al.
- Findings: Median overall survival 37 vs 29 months; hazard ratio 0.87 (non-inferior).; Median progression-free survival 16 vs 12 months.
- What it means: Carboplatin-paclitaxel is the chemotherapy standard for uterine carcinosarcoma in all stages, now combined with dostarlimab in advanced disease following RUBY, which included carcinosarcoma.
- Caveats: Non-inferiority design; the trend favouring carboplatin was not tested for superiority.; Adjuvant radiotherapy was not standardised.

## Sources

- J Clin Oncol 2022: https://doi.org/10.1200/JCO.21.02050
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35007153/

## Connected records

- cancers: [Uterine carcinosarcoma](https://onco.cc/cancers/uterine-carcinosarcoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-gog-0261-carcinosarcoma-powell-jco-2022.json